Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial ResultsGlobeNewsWire • 08/08/23
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality AssuranceGlobeNewsWire • 06/06/23
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/23
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial ResultsGlobeNewsWire • 05/10/23
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial ResultsGlobeNewsWire • 03/15/23
Goldman Sachs Has 5 Stellar Stocks to Buy Under $10 With Up to 735% Upside Potential24/7 Wall Street • 03/04/23
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care ConferenceGlobeNewsWire • 02/28/23
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in OncologyGlobeNewsWire • 01/09/23
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 WeeksZacks Investment Research • 12/12/22
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology MeetingGlobeNewsWire • 12/11/22
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical TrialGlobeNewsWire • 12/07/22
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 WeeksZacks Investment Research • 11/22/22
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial ResultsGlobeNewsWire • 11/08/22
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742GlobeNewsWire • 11/08/22
Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% to 800% Upside Potential24/7 Wall Street • 10/29/22
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022GlobeNewsWire • 10/12/22
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid LeukemiaGlobeNewsWire • 08/22/22
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AMLPRNewsWire • 08/16/22
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/09/22